The PCSK9 inhibitor evolocumab increased the risk of all-cause mortality in the FOURIER trial when followed for 3.4 years.

“if you go out to the data for 3.5 years or 3.4 years what you will find is that it was a very different story that it did not have any benefit for M myocardial infarction or stroke and it increased the risk of all cause mortality”

“evolocumab increased the risk of all cause mortality in the Fier trial the main results article presented mortality s censored that's a big word today in 2020 censored at the medium followup of 22.2 the median followup of 2.2 excuse me years and this was used in previous reviews clinical trials.gov provided mortality for the full length of followup of all patients at 3.4 years and as I said earlier at 3.4 years the results look very very differently”